default author photo

Huilai Zhang

Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy

SCHOLARLY PAPERS

7

DOWNLOADS

459

TOTAL CITATIONS

1

Scholarly Papers (7)

1.

The Age-Adjusted International Prognostic Index 2 (A-Flipi2) for Elderly Patients with Follicular Lymphoma

Number of pages: 31 Posted: 08 Aug 2024
Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University - Department of Pathology, Tianjin Medical University - Department of Pathology, Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy and Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy
Downloads 135 (540,814)

Abstract:

Loading...

follicular lymphoma, Elderly patients, prognostic factors, Prognostic models

2.

Tumoral Foxp3 Expression Predicts Worse Outcomes in Diffuse Large B Cell Lymphoma

Number of pages: 30 Posted: 03 Jul 2024
Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy and Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy
Downloads 65 (916,100)

Abstract:

Loading...

Diffuse large B-cell lymphoma, FoxP3, FoxP3+ tumour-infiltrating lymphocytes, Tumoral FoxP3, Prognosis

3.

Evidence of Cure for Extranodal Nasal-Type NK/T-Cell Lymphoma with Modern Treatment: An Analysis of the CLCG Database

Number of pages: 34 Posted: 31 May 2022
Chinese Academy of Medical Sciences - National Clinical Research Center for Cancer, Huazhong University of Science and Technology - Union Hospital, First Medical Center of Chinese PLA General Hospital, Government of the People's Republic of China - Beijing Hospital, Anhui Provincial Hospital, Fujian Medical University - Department of Radiation Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Peking Union Medical College Hospital, Hebei Medical University - Fourth Hospital, Nanchang University - Second Affiliated Hospital, Chinese Academy of Sciences (CAS) - Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Shanxi Cancer Hospital, Fujian Provincial Cancer Hospital, Guizhou Medical University (Guiyang Medical University) - Affiliated Hospital, Central South University - Hunan Cancer Hospital, Government of the People's Republic of China - Xijing Hospital, Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy, Government of the People's Republic of China - Fifth Medical Center of Chinese PLA General Hospital, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China, Sun Yat-sen University (SYSU) - State Key Laboratory of Oncology in South China, Chongqing University Cancer Hospital, Qinghai University - Qinghai University Affiliated Hospital, Qinghai University - Qinghai University Affiliated Hospital, Nanjing Medical University - Jiangsu Cancer Hospital, Soochow University - Department of Radiation Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Radiation Oncology and Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Radiation Oncology
Downloads 64 (924,743)

Abstract:

Loading...

Extranodal nasal-type NK/T-cell lymphoma, Cure fraction, Relative survival, Prognosis, Non-anthracycline-based chemotherapy, Radiotherapy

4.

RNA-Editing-Initiated MAVS Signaling is a Key Epitranscriptomic Alteration in Human B Cell Lymphoma

Number of pages: 62 Posted: 20 Sep 2021
German Cancer Research Center (DKFZ) - Division of Immune Diversity, Karolinska Institutet - Department of Biosciences and Nutrition, Tianjin Medical University - Department of Lymphoma, Karolinska Institutet - Department of Biosciences and Nutrition, Tianjin Medical University - Department of LymphomaTianjin Medical University - Key Laboratory of Cancer Prevention and Therapy, German Cancer Research Center (DKFZ) - Division of Immune Diversity, German Cancer Research Center (DKFZ) - Division of Immune Diversity, Karolinska Institutet - Department of Biosciences and Nutrition, German Cancer Research Center (DKFZ) - Division of Immune Diversity, German Cancer Research Center (DKFZ) - Research Group "Dynamics of Early Viral Infection and the Innate Antiviral Response", University of Tübingen - Interfaculty Institute of Biochemistry, University of Tübingen - Interfaculty Institute of Biochemistry, University of Tübingen - Interfaculty Institute of Biochemistry, Uppsala University - Department of Immunology, Genetics and Pathology, Clinical and Experimental Oncology, Uppsala University - Department of Immunology, Genetics and Pathology, Clinical and Experimental Oncology, Karolinska Institutet - Hematology Unit, Karolinska InstitutetKarolinska Institutet - Hematology Unit, Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy, German Cancer Research Center (DKFZ) - Research Group "Dynamics of Early Viral Infection and the Innate Antiviral Response", German Cancer Research Center (DKFZ) - Division of Immune Diversity (D150) and Karolinska Institutet - Department of Biosciences and Nutrition
Downloads 54 (1,020,567)
Citation 1

Abstract:

Loading...

Epitranscriptomics, RNA editing, cancer, B cell lymphoma, disease progression, RLR pathway, targeted base editing therapeutics

5.

Comprehensive Analysis of Peripheral T-Cell and Natural Killer/T-Cell Lymphoma in Asian Patients: A Multinational, Multicenter, Prospective Registry Study in Asia

Number of pages: 45 Posted: 17 Dec 2020
Sungkyunkwan University - Samsung Medical Center, Peking University - Peking University Cancer Hospital & Institute, Sungkyunkwan University - Division of Hematology-Oncology, University of Ulsan - Department of Oncology, National Cheng Kung University - Division of Hematology and Oncology, Seoul National University - Department of Internal Medicine, Anam Hospital Korea University Medical Center - Department of Internal Medicine, Division of Hematology-Oncology, Kosin University Gospel Hospital, Department of Internal Medicine, Chungnam National University College of Medicine, Chinese Academy of Medical Sciences - National Cancer Center, Department of Haematology-Oncology, National University Health System, University of Indonesia (UI), Shanghai Jiao Tong University (SJTU) - State Key Laboratory of Medical Genomics, Keimyung University - Dongsan Medical Center, Department of Hematology-Oncology, Konkuk University Medical Center, Subang Jaya Medical Center, Division of Hemato-Oncology, Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Fudan University Shanghai Cancer Center, Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy, Korea Institute of Radiological and Medical Sciences, Department of Internal Medicine, Chungnam National University College of Medicine, Division of Hematology and Oncology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Raffles Cancer Centre, Division of Hematology–Oncology, Department of Internal Medicine, Jeonbuk National University Hospital, Jeonbuk National University, Department of Hematology and Medical Oncology, College of Medicine, Kyung Hee University, Division of Hematology–Oncology, Ewha Womans University Mokdong Hospital, Ewha Womans University, Dong-A University, School of Medicine, Dong-A University Hospital, Department of Internal Medicine, Department of Internal Medicine, Wonkwang University School of Medicine, Chungnam National University, Inje University - Department of Medicine, Department of Internal Medicine, Soonchunhyang University College of Medicine, Division of Hematology and Oncology, Department of Internal Medicine, Ulsan University Hospital, Ulsan University College of Medicine, Sungkyunkwan University - Samsung Medical Center, Peking University - Key Laboratory of Carcinogenesis and Translational Research and Sungkyunkwan University - Division of Hematology-Oncology
Downloads 54 (1,020,567)

Abstract:

Loading...

Lymphoma, T-Cell, Peripheral; Lymphoma, Extranodal NK-T-Cell; Incidence; Therapeutics; Survival; Prognosis

6.

Clinicopathologic Characteristics, Outcomes, and Prognostic Factors of Angioimmunoblastic T-Cell Lymphoma in China

Number of pages: 26 Posted: 14 Mar 2022
affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Hematology
Downloads 46 (1,109,210)

Abstract:

Loading...

7.

Efficacy and Safety of Geptanolimab (GB226) for Relapsed or Refractory Peripheral T-Cell Lymphoma: An Open-Label Phase 2 Study (Gxplore-002)

Number of pages: 28 Posted: 13 Oct 2020
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Jiangsu Cancer Hospital - Department of Oncology, Linyi Cancer Hospital - Department of Oncology, Huazhong University of Science and Technology - Department of Lymphoma, Capital Medical University - Department of Hematology, Zhengzhou University - Department of Oncology, Guangxi Medical University - Department of Hematology, Lymphoma and Pediatric Oncology, Guangxi Medical University - Department of Oncology, Henan Cancer Hospital - Department of Hematology, Jiangsu Province Hospital - Department of Hematology, Shanghai Oriental Hospital - Department of Oncology, Sun Yat-Sen University (SYSU) - Department of Hematology, Gansu Provincial Cancer Hospital - Department of Hematology, Hebei Medical University - Department of Hematology, Zhejiang Cancer Hospital - Department of Lymphoma, Sun Yat-Sen University (SYSU) - Department of Oncology, Hainan General Hospital - Department of Oncology, Shanxi Medical University - Department of Hematology, Tianjin Medical University - Key Laboratory of Cancer Prevention and Therapy, Sichuan University - Department of Hematology, Sichuan University - Department of Oncology, Hunan Cancer Hospital - Department of lymphoma,, Jiangxi Cancer Hospital - Department of Oncology, The Fifth Medical Center of The General Hospital of The People's Liberation Army - Department of Lymphoma, Peking University - Department of Hematology, Guangzhou Medical University - Department of Oncology, Guangdong Academy of Medical Sciences - Department of Hematology, Government of the People's Republic of China - Tangdu Hospital - Department of Hematology, Lanzhou University - Department of Hematology, Southeast University - Department of Hematology, Nanfang Hospital - Department of Hematology, Dalian University - Department of Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Medical Oncology, Genor Biopharma Co., Ltd. - Department of Medical Science and Genor Biopharma Co., Ltd. - Department of Medical Science
Downloads 41 (1,170,409)

Abstract:

Loading...

peripheral T-cell lymphoma, PD-1 inhibitor, immunotherapy